{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-069077","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.056168+00:00","generated_at":"2026-06-01T06:16:05.724310+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Axsome settles Sunosi patent litigation with Unichem; generic entry June 30, 2042","bullets":["Settlement resolves Hatch-Waxman litigation over Sunosi (solriamfetol) following Unichem's ANDA.","Unichem may begin selling generic Sunosi on June 30, 2042, subject to pediatric exclusivity extension.","Agreement subject to FTC and DOJ review; other Sunosi patent cases remain pending in New Jersey.","Axsome maintains Sunosi exclusivity until at least 2042 unless earlier triggering events occur."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-069077","json":"https://secwatch.observer/filing/0000950170-24-069077.json","markdown":"https://secwatch.observer/filing/0000950170-24-069077.md","text":"https://secwatch.observer/filing/0000950170-24-069077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024069077/0000950170-24-069077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024069077/axsm-20240605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:16:05.724310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}